Investor Presentaiton

20% 15% 10% 5% Even excluding COVID-19 clinical testing and reagents, Eurofins organic revenue growth continues to significantly outperform TIC industry peers H1 2020 H1 2021 H1 2021 vs. H1 20192 0%- -5% -10% -15% 3 3 * eurofins CAGR H1 2019-2021 3 3 1 Corrected for EUR 62m estimated missing revenues from the cyber-attack impact of June 2019 2 3 Based on public information, using each of the respective companies' Alternative Performance Measures (APM) definitions, H1 2021 vs. H1 2019 calculated by simple multiplication of the organic growth % for the two periods TICS ex ERF = average organic growth of historic TIC leaders (SGS, Intertek and Bureau Veritas) - Eurofins 1 Average TICS ex ERF 3 -SGS Bureau Veritas Intertek 20

View entire presentation